Dravet Syndrome Market Report 2026

The dravet syndrome market size has grown strongly in recent years. It will grow from $0.4 billion in 2025 to $0.44 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rare epilepsy awareness, scn1a gene discovery, anticonvulsant drug development, pediatric neurology specialization, orphan drug incentives.

The dravet syndrome market size is expected to see strong growth in the next few years. It will grow to $0.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to gene therapy research, precision neurology treatments, early genetic screening, patient registry expansion, supportive care innovation. Major trends in the forecast period include growing development of targeted antiepileptic drugs, rising use of genetic testing for diagnosis, increased focus on rare disease therapies, adoption of cannabidiol-based treatments, expansion of multidisciplinary care models.

The rising prevalence of neurological disorders is expected to drive the growth of the Dravet syndrome market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, and nervous system, leading to impairments in cognition, movement, sensation, and overall neurological function. Their prevalence is increasing due to aging populations, lifestyle changes, environmental factors, improved diagnostic capabilities, and higher rates of autoimmune and infectious neurological diseases. The Dravet syndrome market supports this trend by advancing research into genetic mutations, neuronal excitability, and targeted therapies, contributing to broader innovation in neurological diseases. For example, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit health organization, 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections suggesting this number could rise to 13.8 million by 2060. Therefore, the increasing prevalence of neurological disorders is driving growth in the Dravet syndrome market.

Companies in the Dravet syndrome market are focusing on advancements in precision medicine, such as RNA-based therapies, to develop targeted treatments that address the underlying genetic mutations of the disorder, improving efficacy while reducing side effects. RNA-based therapies use RNA molecules to modulate gene expression or protein production, correcting molecular defects at their source rather than merely managing symptoms. For instance, in December 2024, Stoke Therapeutics Inc., a US-based biotechnology company, received U.S. FDA approval for zorevunersen to treat Dravet syndrome. This therapy is designed to increase expression of the SCN1A gene, which is commonly mutated in patients, thereby addressing the root genetic deficiency. By leveraging RNA-based precision medicine to restore proper neuronal function, zorevunersen can potentially reduce seizure frequency and improve cognitive outcomes, representing a significant advancement in targeted Dravet syndrome therapeutics.

In April 2024, Harmony Biosciences, a US-based pharmaceutical company, acquired Epygenix Therapeutics Inc. for an undisclosed amount. Through this acquisition, Harmony Biosciences aims to expand its rare epilepsy portfolio by integrating Epygenix’s lead candidate, EPX-100, which is being developed for Dravet syndrome and Lennox-Gastaut syndrome. Epygenix Therapeutics Inc. is a US-based biotechnology company focused on developing drugs for Dravet syndrome.

Major companies operating in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, Ovid Therapeutics Inc.

North America was the largest region in the dravet syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dravet syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dravet syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dravet syndrome market by increasing costs of imported specialty drugs, genetic testing kits, and diagnostic equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported rare disease therapies. However, tariffs are encouraging domestic manufacturing of orphan drugs and strengthening regional rare disease supply chains.

The dravet syndrome market research report is one of a series of new reports that provides dravet syndrome market statistics, including dravet syndrome industry global market size, regional shares, competitors with a dravet syndrome market share, detailed dravet syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the dravet syndrome industry. This dravet syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dravet syndrome is a rare and severe form of epilepsy that begins in infancy, characterized by prolonged and frequent seizures that are often resistant to treatment. It is studied for genetic mutations in the SCN1A gene and for developing targeted therapies to manage seizures and improve patient outcomes.

The main treatment and management options for Dravet syndrome include seizure medications, the ketogenic diet, vagus nerve stimulation, and others. Seizure medications are used to prevent or reduce the frequency and severity of seizures in epilepsy and other neurological disorders. Diagnostic tests include magnetic resonance imaging (MRI), electroencephalography (EEG), sodium voltage-gated channel alpha subunit 1 testing, and others. Routes of administration include parenteral and oral methods, among others. End users include pharmaceutical companies, hospitals, diagnostic laboratories, and academic and research institutes.

The dravet syndrome market consists of revenues earned by entities that provide services such as advanced genetic screening, medical consultation and diagnosis, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The dravet syndrome market also includes sales of genetic testing kits, anticonvulsant medications, and emerging gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.